Jefferies Maintains Buy Following an Analysis on Integra LifeSciences (IART) TEI Acquisition
Get Alerts IART Hot Sheet
Rating Summary:
10 Buy, 13 Hold, 3 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 11
Join SI Premium – FREE
Jefferies maintains a Buy rating and $67.00 price target on Integra LifeSciences (NASDAQ: IART) following a preliminary analysis of IART's TEI acquisition. Integra projects TEI revenues to grow high-single digits. The deal is expected to close in 3Q.
Analyst Raj Denhoy commented, "Our preliminary analysis of Integra's acquisition of TEI points to a good deal for the company. TEI adds to Integra's regenerative product portfolio and adds to the sales & marketing infrastructure in wound care ahead of the upcoming DFU launch. Financially, the transaction will be immediately accretive: our initial math suggests EPS accretion of $0.25-$0.30 in 2016."
For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.
Shares of Integra LifeSciences closed at $68.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Recruit Holdings Co., Ltd (6098:JP) (RCRUY) PT Raised to JPY7,800 at Jefferies, 'emerged stronger since the last earnings season'
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK190 at RBC Capital, 'showing some promising signs '
- Monness, Crespi, Hardt Downgrades Palantir Technologies Inc. (PLTR) to Sell on 'egregiously rich valuation... darkest days of this economic downturn are ahead of us'
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsRelated Entities
Jefferies & Co, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!